Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Meta-analysis: anti-BCMA CAR-T in R/R multiple myeloma

Nico Gagelmann • 26 Aug 2020
EBMT 2020
Multiple Myeloma CAR-T

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from a meta-analysis evaluating the outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nico Gagelmann

0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024
1:22
The role of splenic irradiation in transplant for patients with myelofibrosis
Nico Gagelmann • 15 Feb 2024
1:41
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Nico Gagelmann • 15 Feb 2024
2:03
Looking to the future in the field of transplantation
Nico Gagelmann • 9 Dec 2023

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals